1-8 of 8
Angela Coxon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Petra Deegen, Oliver Thomas, Olivier Nolan-Stevaux, Shyun Li, Joachim Wahl, Pamela Bogner, Famke Aeffner, Matthias Friedrich, Michael Z. Liao, Katja Matthes, Doris Rau, Benno Rattel, Tobias Raum, Peter Kufer, Angela Coxon, Julie M. Bailis
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2928–2937.
https://doi.org/10.1158/1078-0432.CCR-20-3725
Published: 15 May 2021
View article titled, The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Open the PDF for The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Michael J. Giffin, Keegan Cooke, Edward K. Lobenhofer, Juan Estrada, Jinghui Zhan, Petra Deegen, Melissa Thomas, Christopher M. Murawsky, Jonathan Werner, Siyuan Liu, Fei Lee, Oliver Homann, Matthias Friedrich, Joshua T. Pearson, Tobias Raum, Yajing Yang, Sean Caenepeel, Jennitte Stevens, Pedro J. Beltran, Jude Canon, Angela Coxon, Julie M. Bailis, Paul E. Hughes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1526–1537.
https://doi.org/10.1158/1078-0432.CCR-20-2845
Published: 01 March 2021
View article titled, AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Open the PDF for AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

Christina L. Zuch de Zafra, Flordeliza Fajardo, Wendy Zhong, Matthew J. Bernett, Umesh S. Muchhal, Gregory L. Moore, Jennitte Stevens, Ryan Case, Joshua T. Pearson, Siyuan Liu, Patricia L. McElroy, Jude Canon, John R. Desjarlais, Angela Coxon, Mercedesz Balazs, Olivier Nolan-Stevaux
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (13): 3921–3933.
https://doi.org/10.1158/1078-0432.CCR-18-2752
Published: 01 July 2019
View article titled, Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
Open the PDF for Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release in another window
Includes: Supplementary data
Journal Articles

Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors

Tim J. Kruser, Deric L. Wheeler, Eric A. Armstrong, Mari Iida, Kevin R. Kozak, Albert J. van der Kogel, Johan Bussink, Angela Coxon, Anthony Polverino, Paul M. Harari
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3639–3647.
https://doi.org/10.1158/1078-0432.CCR-09-3385
Published: 14 July 2010
View article titled, Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors
Open the PDF for Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors in another window
Includes: Supplementary data
Journal Articles

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan-Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 699–710.
https://doi.org/10.1158/1078-0432.CCR-09-1365
Published: 14 January 2010
View article titled, Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Angela Coxon, Tammy Bush, Douglas Saffran, Stephen Kaufman, Brian Belmontes, Karen Rex, Paul Hughes, Sean Caenepeel, James B. Rottman, Andrew Tasker, Vinod Patel, Richard Kendall, Robert Radinsky, Anthony Polverino
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 110–118.
https://doi.org/10.1158/1078-0432.CCR-08-1155
Published: 31 December 2008
View article titled, Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors
Open the PDF for Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors in another window
Journal Articles

AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts

H. Toni Jun, Jan Sun, Karen Rex, Robert Radinsky, Richard Kendall, Angela Coxon, Teresa L. Burgess
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22): 6735–6742.
https://doi.org/10.1158/1078-0432.CCR-06-2969
Published: 15 November 2007
View article titled, AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts
Open the PDF for AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts in another window
Journal Articles

c-Met Ectodomain Shedding Rate Correlates with Malignant Potential

Gagani Athauda, Alessio Giubellino, Jonathan A. Coleman, Christine Horak, Patricia S. Steeg, Ming-Jung Lee, Jane Trepel, Jennifer Wimberly, Jan Sun, Angela Coxon, Teresa L. Burgess, Donald P. Bottaro
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4154–4162.
https://doi.org/10.1158/1078-0432.CCR-06-0250
Published: 20 July 2006
View article titled, c-Met Ectodomain Shedding Rate Correlates with Malignant Potential
Open the PDF for c-Met Ectodomain Shedding Rate Correlates with Malignant Potential in another window